Will Johnson & Johnson submit a BLA for IMAAVY to the FDA by 23 October 2026?
Posted 2026-08-24 — 60 days before the deadline, stated before the outcome.
Johnson & Johnson is a multinational pharmaceutical company, and the FDA is the U.S. agency that reviews drug applications. A Biologics License Application is the regulatory submission required to market a new biologic therapy for a specific medical condition.
The claim
Johnson & Johnson submits a Biologics License Application (BLA) for IMAAVY (nipocalimab-aahu) for the treatment of warm autoimmune hemolytic anemia (wAIHA) to the FDA by October 23, 2026.
Reasoning trace
- Parallel: Eli Lilly's albiglutide/semaglutide approval process (2014-2017), sim=9
- Positive Phase 2/3 data for a 'first-in-class' therapy in an unmet medical need (wAIHA) triggers immediate filing preparation to capture the 'first-to-market' regulatory advantage.
- The signal explicitly notes 'FDA Priority Review' and 'no FDA-approved therapies,' mirroring the rapid-filing dynamic of early GLP-1 agonists where companies file within 1-3 months of definitive trial success to expedite review.
Evidence so far
6 confirming · 0 denying signals · 3 verified · 1 broken assumptions. The evidence itself is part of the full dossier.
Probability history
Updated 18 times since mint (last on 2026-10-04) — 28% at mint → 79% today.
What to watch
- precondition Johnson & Johnson submits the Biologics License Application (BLA) for nipocalimab-aahu to the FDA
- leading indicator The FDA publishes a public notice or letter confirming the grant of Breakthrough Therapy or Priority Review designation for nipocalimab-aahu in wAIHA
The full dossier behind this prediction — the evidence trail, the risk analysis, the monetization scenarios — is available on request: [email protected].
Probabilities are calibrated against the system's own resolved history; after the deadline the outcome is resolved and audited — including the calls we get wrong. Nothing on this page is investment advice.